Skip to main content
Clinical Trials/NCT01888315
NCT01888315
Unknown
Phase 1

Safety and Efficacy Study Investigating the Effects of Catheter-based Renal Denervation on Different Organ Systems in Patients With Increased Sympathetic Activity

University Hospital, Saarland1 site in 1 country1,000 target enrollmentJanuary 2011

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Hypertension
Sponsor
University Hospital, Saarland
Enrollment
1000
Locations
1
Primary Endpoint
Safety and efficacy of renal denervation
Last Updated
12 years ago

Overview

Brief Summary

The study is aiming to document the long-term safety and effectiveness of renal denervation in patients with hypertension and other diseases characterized by elevated sympathetic drive. Catheter-based renal denervation will be performed using CE marked, percutaneous, systems.

Detailed Description

Inclusion Criteria 1. Individual is 18 years of age. 2. Individual agrees to have all procedures performed, and is competent and willing to provide written, informed consent to participate in the registry. 3. Patient scheduled for renal sympathetic denervation using market-released device. Exclusion Criteria 1. In the eyes of the treating physician, the renal artery anatomy would interfere with safe cannulation of the renal artery or meets local standards for surgical repair. 2. Individual has any serious medical condition, which in the opinion of the treating physician may adversely affect the safety and/or effectiveness of the participant (i.e., patients with clinically significant peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders such as thrombocytopenia, hemophilia, significant anemia, etc.).

Registry
clinicaltrials.gov
Start Date
January 2011
End Date
January 2021
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University Hospital, Saarland
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Safety and efficacy of renal denervation

Time Frame: Baseline to 6 months

Effect on blood pressure including office, ABPM, and home-based measurements. Number of adverse events (death, stroke, myocardial infarction, new dialysis, and congestive heart failure). Changes of antihypertensive medications. Effects on renal function assessed with glomerular filtration rate. Renovascular safety (renal artery stenosis) assessed by duplex ultrasound.

Secondary Outcomes

  • Effect of renal denervation on different organ systems.(Baseline, 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 months)
  • Safety and efficacy of renal denervation(Baseline, 3, 12, 18, 24, 30, 36, 42, 48, 54, 60 months)

Study Sites (1)

Loading locations...

Similar Trials